Other equities analysts also recently issued research reports about the company. Cantor Fitzgerald restated a buy rating on shares of Tivity Health in a research report on Monday, April 22nd. Zacks Investment Research upgraded Focus Financial Partners from a hold rating to a buy rating and set a $31.00 price objective for the company in a research report on Monday, June 24th. Finally, William Blair reiterated a market perform rating on shares of W W Grainger in a research report on Monday, April 22nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. The company presently has an average rating of Hold and an average price target of $61.33.
Shares of EXPO stock opened at $60.15 on Tuesday. The stock has a 50 day moving average price of $57.98. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.22 and a quick ratio of 4.22. Exponent has a 12 month low of $44.44 and a 12 month high of $60.38. The company has a market cap of $3.07 billion, a P/E ratio of 42.87 and a beta of 0.44.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 21st. Shareholders of record on Friday, June 7th were given a $0.16 dividend. The ex-dividend date of this dividend was Thursday, June 6th. This represents a $0.64 annualized dividend and a yield of 1.06%. Exponent’s payout ratio is 51.20%.
In other Exponent news, Director Carol Lindstrom sold 1,800 shares of Exponent stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $56.92, for a total value of $102,456.00. Following the completion of the transaction, the director now owns 3,212 shares in the company, valued at approximately $182,827.04. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.30% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. Bronfman E.L. Rothschild L.P. raised its position in Exponent by 580.9% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 926 shares of the business services provider’s stock valued at $47,000 after purchasing an additional 790 shares during the last quarter. Bremer Bank National Association bought a new position in Exponent in the 1st quarter valued at $55,000. Quadrant Capital Group LLC increased its stake in shares of Exponent by 961.2% in the 1st quarter. Quadrant Capital Group LLC now owns 1,040 shares of the business services provider’s stock valued at $57,000 after buying an additional 942 shares during the period. Ellis Investment Partners LLC acquired a new stake in shares of Exponent in the 1st quarter valued at $90,000. Finally, NN Investment Partners Holdings N.V. acquired a new stake in shares of Exponent in the 2nd quarter valued at $91,000. Hedge funds and other institutional investors own 88.80% of the company’s stock.
Exponent Company Profile
Exponent, Inc, together with its subsidiaries, operates as a science and engineering consulting company worldwide. Its services include analysis of product development, product recall, regulatory compliance, and the discovery of potential problems related to products, people, property, and impending litigation.
Featured Article: Why is the LIBOR significant?
Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.